Table 1.
Blood biomarkers in healthy controls and in patients with compensated cirrhosis with subclinical PH and CSPH.
| Baseline |
1 year† |
2 year‡ |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | p values | Median | IQR | p intra | Median | IQR | p intra | |
| IL-6 (pg/ml) | |||||||||
| Controls (n = 35) | 1.66 | 1.01-2.64 | <0.05,# | <0.05 | 0.12 | ||||
| Cirrhosis with subclinical PH (n = 54) | 1.5 | 1.12-2.66 | |||||||
| Cirrhosis with CSPH (n = 164) | 2.32 | 1.31-3.56 | 3.03 | 1.39-5.25 | 2.71 | 1.53-4.15 | |||
| TNF (ng/ml) | |||||||||
| Controls (n = 35) | 6.41 | 5.3-7.44 | 0.52 | 0.59 | 0.25 | ||||
| Cirrhosis with subclinical PH | 6.46 | 5.61-7.8 | |||||||
| Cirrhosis with CSPH | 6.1 | 4.1-8.4 | 6.83 | 4.77-8.79 | 6.58 | 3.96-9.88 | |||
| vWF (ng/ml) | |||||||||
| Controls | 2.95 | 1.46-5.13 | <0.01∗,# | 0.58 | 0.43 | ||||
| Cirrhosis with subclinical PH | 3.39 | 1.87-5.37 | |||||||
| Cirrhosis with CSPH | 6.0 | 3.61-9.81 | 4.79 | 2.78-9.18 | 4.25 | 2.59-9.96 | |||
| C-reactive protein (mg/dl) | |||||||||
| Controls | 0.59 | 0.35-1.21 | 0.06 | 0.6 | 0.46 | ||||
| Cirrhosis with subclinical PH | 0.85 | 0.6-1.08 | |||||||
| Cirrhosis with CSPH | 0.52 | 0.19-1.17 | 0.55 | 0.18-1.43 | 0.5 | 0.2-1.41 | |||
| CD163 (ng/ml) | |||||||||
| Controls (n = 35) | 258.74 | 210.7- 362.4 | <0.01∗,# | 0.5 | 0.6 | ||||
| Cirrhosis with subclinical PH | 252.85 | 205.6-305.55 | |||||||
| Cirrhosis with CSPH | 857.72 | 605.5-1,117 | 820.35 | 524.2-1,087.1 | 787.67 | 534.37-1,174.81 | |||
| CD14 (mg/ml) | |||||||||
| Controls | 1.23 | 0.84-1.48 | 0.2 | 0.77 | 0.4 | ||||
| Cirrhosis with subclinical PH | 1.49 | 0.98-1.88 | |||||||
| Cirrhosis with CSPH | 1.28 | 1.07-1.6 | 1.27 | 1-1.58 | 1.22 | 1.02-1.51 | |||
| LBP (μg/ml) | |||||||||
| Controls | 6.2 | 4.1-6.9 | 0.66 | 0.89 | 0.25 | ||||
| Cirrhosis with subclinical PH | 5.9 | 5.4-7.1 | |||||||
| Cirrhosis with CSPH | 6.05 | 4.65-7.39 | 6.31 | 5.26-7.62 | 6.75 | 5.05-8.26 | |||
| LPS (IU/ml) | |||||||||
| Controls | 0.05 | 0.03-0.08 | <0.01∗,# | <0.01 | <0.01 | ||||
| Cirrhosis with subclinical PH | 0.09 | 0.05-0.12 | |||||||
| Cirrhosis with CSPH | 0.20 | 0.11-0.36 | 0.54 | 0.21-1.07 | 0.58 | 0.28-1.14 | |||
| FABP (ng/ml) | |||||||||
| Controls | 0.31 | 0.19- 0.50 | <0.01∗,# | 0.95 | 0.18 | ||||
| Cirrhosis with subclinical PH | 0.46 | 0.31-0.53 | |||||||
| Cirrhosis with CSPH | 0.72 | 0.52-1.04 | 0.73 | 0.419-1.01 | 0.88 | 0.56-1.52 | |||
| Haptoglobin (mg/L) | |||||||||
| Controls | 721.5 | 425.9-988.5 | <0.01∗,# | 0.22 | 0.45 | ||||
| Cirrhosis with subclinical PH | 750.2 | 589-830 | |||||||
| Cirrhosis with CSPH | 213.4 | 72.94-349.2 | 224.3 | 98.6-366.7 | 227.4 | 76.94-381.8 | |||
p values: controls vs. cirrhosis with subclinical PH vs. cirrhosis with CSPH (Kruskal-Wallis test with Bonferroni correction).
p intra: baseline vs. 1-year and 2-year, respectively, in cirrhosis with CSPH (Wilcoxon signed-rank test).
p values <0.05 indicated in bold.
CSPH, clinically significant portal hypertension; FABP, fatty acid binding protein; LBP, lipopolysaccharide-binding protein; LPS, lipopolysaccharide; PH, portal hypertension; vWF, von Willebrand factor.
∗
Controls vs. cirrhosis with CSPH.
#
Cirrhosis with subclinical PH vs. cirrhosis with CSPH.
†
Cirrhosis with CSPH (n = 108).
‡
Cirrhosis with CSPH (n = 82).